The loss of the senses of smell (anosmia) and taste (ageusia) are rather common disorders, affecting up to 20% of the adult population. Yet, this condition has not received the attention it deserves, most probably because per se such a disorder is not life threatening. However, loss of olfactory function significantly reduces the quality of life of the affected patients, leading to dislike in food and insufficient, exaggerated or unbalanced food intake, unintentional exposure to toxins such as household gas, social isolation, depression, and an overall insecurity. Not only is olfactory dysfunction rather prevalent in the healthy population, it is, in many instances, also a correlate or an early indicator of a panoply of diseases. Importantly, olfactory dysfunction is linked to the two most prominent neurodegenerative disorders, Parkinson's disease and Alzheimer's disease. Anosmia and hyposmia (reduced sense of smell) affect a majority of patients years before the onset of cognitive or motor symptoms, establishing olfactory dysfunction as early biomarker that can enable earlier diagnosis and preventative treatments. In the current health crisis caused by SARS-CoV2, anosmia and dysgeusia as early-onset symptoms in virus-positive patients may prove to be highly relevant and crucial for pre-symptomatic Covid-19 detection from a public health perspective, preceding by days the more classical respiratory tract symptoms such as cough, tightness of the chest or fever. Thus, the olfactory system seems to be at the frontline of pathologic assault, be it through pathogens or insults that can lead to or at least associate with neurodegeneration. The aim of this review is to assemble current knowledge from different medical fields that all share a common denominator, olfactory/gustatory dysfunction, and to distill overarching etiologies and disease progression mechanisms.

The controlled covalent functionalization of the graphene channel of a field effect transistor, based on interdigitated gold electrodes (source and drain), via electrochemical grafting, using specifically designed aryl diazonium species is demonstrated to allow the simple fabrication of a general platform for (bio)sensing applications. The electrochemical grafting of a protected ethynylphenyl diazonium salt leads to the deposition of only a monolayer on the graphene channel. This controlled covalent functionalization of the graphene channel results in a charge mobility of the GFET of 1739 ± 376 cm² V⁻¹ s⁻¹ and 1698 ± 536 cm² V⁻¹ s⁻¹ for the holes and electrons, respectively, allowing their utilization as (bio)sensors. After deprotection, a dense and compact ethynylphenyl monolayer is obtained and allows the immobilization of a wide range of (bio)molecules by a “click” chemistry coupling reaction (Huisgen 1,3-dipolar cycloaddition). This finding opens promising options for graphene-based (bio)sensing applications.

In this short review, we summarize the design and implementation of organic semiconducting materials-based field-effect transistors (OFETs) and the fabrication and use of reduced graphene-oxide field-effect transistors (rGO–FETs) as flexible transducers for electronic biosensing. We demonstrate that these platforms allow for the quantitative, in situ, and in real time monitoring of bio-affinity reactions between analytes from solution to the surface-immobilized receptors. The examples given include the binding of anti-bovine serum albumin (BSA) antibodies to their antigen, BSA, covalently attached to the channel of an OFET, or the reverse mode of operation, i.e., the binding of BSA from solution to the antibodies immobilized on a rGO transistor. Finally, we will discuss a few results obtained with odorant binding proteins used as receptors on a rGO–FET transducer for the realization of a biomimetic smell sensor.